{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:47:26Z","timestamp":1789040846263,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002336","name":"Simmons Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA271497"],"award-info":[{"award-number":["R01 CA271497"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA280389"],"award-info":[{"award-number":["R01 CA280389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA243386"],"award-info":[{"award-number":["R01 CA243386"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 CA236399"],"award-info":[{"award-number":["R01 CA236399"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.xcrm.2024.101645","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:10:36Z","timestamp":1721142636000},"page":"101645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling"],"prefix":"10.1016","volume":"5","author":[{"given":"Meiling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitty","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Sau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3749-2902","authenticated-orcid":false,"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101645_bib1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1377\/hlthaff.2022.00113","article-title":"National Health Expenditure Projections, 2021-30: Growth To Moderate As COVID-19 Impacts Wane","volume":"41","author":"Poisal","year":"2022","journal-title":"Health Aff."},{"key":"10.1016\/j.xcrm.2024.101645_bib2","series-title":"U.S. Health in International Perspective: Shorter Lives, Poorer Health","first-page":"11","article-title":"U.S. Health in International Perspective: Shorter Lives, Poorer Health","author":"Woolf","year":"2013"},{"key":"10.1016\/j.xcrm.2024.101645_bib3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101645_bib5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101645_bib6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101645_bib7","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib8","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib9","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib10","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1158\/0008-5472.CAN-05-0422","article-title":"Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation","volume":"65","author":"Brandts","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","article-title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","volume":"36","author":"R\u00fccker","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101645_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3324\/haematol.2010.034074","article-title":"FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype","volume":"96","author":"Wagner","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2024.101645_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"key":"10.1016\/j.xcrm.2024.101645_bib14","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101645_bib15","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood.2021014586","article-title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib16","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101645_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.26447","article-title":"Gilteritinib clinical activity in relapsed\/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors","volume":"97","author":"Numan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2024.101645_bib18","first-page":"1469","article-title":"Cost-effectiveness of gilteritinib for relapsed\/refractory FLT3(mut+) acute myeloid leukemia","volume":"27","author":"Pandya","year":"2021","journal-title":"J.\u00a0Manag. Care Spec. Pharm."},{"key":"10.1016\/j.xcrm.2024.101645_bib19","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101645_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2024.101645_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like Tyrosine Kinase 3\/FLT3: From Basic Science to Clinical Implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.xcrm.2024.101645_bib22","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.xcrm.2024.101645_bib23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.xcrm.2024.101645_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071583","article-title":"Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review","volume":"8","author":"Franciosi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101645_bib25","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2024.101645_bib26","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"Zhou","year":"2001","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101645_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: from mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metabol."},{"key":"10.1016\/j.xcrm.2024.101645_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101645_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-018-0731-5","article-title":"Metformin induces autophagy and G0\/G1 phase cell cycle arrest in myeloma by targeting the AMPK\/mTORC1 and mTORC2 pathways","volume":"37","author":"Wang","year":"2018","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib30","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib31","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1158\/1078-0432.CCR-22-1665","article-title":"A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer","volume":"28","author":"Han","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib32","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1535-7163.MCT-21-0071","article-title":"Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-Positive AML","volume":"20","author":"Zavorka Thomas","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2024.101645_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abj4009","article-title":"The kinase PLK1 promotes the development of Kras\/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET","volume":"15","author":"Kong","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2024.101645_bib34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00109-018-1663-4","article-title":"Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma","volume":"96","author":"Liu","year":"2018","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101645_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10734","article-title":"Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF\/ERK signaling","volume":"5","author":"Wu","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2024.101645_bib36","doi-asserted-by":"crossref","first-page":"11807","DOI":"10.2147\/OTT.S274451","article-title":"MiR-1224-5p Activates Autophagy, Cell Invasion and Inhibits Epithelial-to-Mesenchymal Transition in Osteosarcoma Cells by Directly Targeting PLK1 Through PI3K\/AKT\/mTOR Signaling Pathway","volume":"13","author":"Jin","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.xcrm.2024.101645_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.xcrm.2024.101645_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2337\/cd21-0009","article-title":"Metformin Extended-Release Oral Solution","volume":"39","author":"Satterwhite","year":"2021","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.xcrm.2024.101645_bib39","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.leukres.2015.09.016","article-title":"Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy","volume":"39","author":"Wang","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib40","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.celrep.2014.10.011","article-title":"The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor","volume":"9","author":"Karlin","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101645_bib41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjc.6601610","article-title":"Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma","volume":"90","author":"Weichert","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101645_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1349-7006.2003.tb01411.x","article-title":"Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers","volume":"94","author":"Takahashi","year":"2003","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2024.101645_bib43","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-14-2890","article-title":"Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer","volume":"22","author":"Ferrarotto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s42003-021-01653-w","article-title":"Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma","volume":"4","author":"Dufies","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2024.101645_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-12-195867","article-title":"Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells","volume":"114","author":"Renner","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib46","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in\u00a0vitro and in\u00a0vivo through a decrease of cyclin D1 level","volume":"27","author":"Ben Sahra","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101645_bib47","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1158\/1078-0432.CCR-17-3167","article-title":"Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer In\u00a0Vitro and In\u00a0Vivo","volume":"24","author":"Thakur","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.leukres.2016.10.004","article-title":"Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine","volume":"50","author":"Sabnis","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117276","article-title":"Inhibition of mTORC1\/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C","volume":"243","author":"Yuan","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.xcrm.2024.101645_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867133","article-title":"Metformin and Thymoquinone Synergistically Inhibit Proliferation of Imatinib-Resistant Human Leukemic Cells","volume":"13","author":"Glamoclija","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101645_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114747","article-title":"Polo-like kinase 1 (PLK1) signaling in cancer and beyond","volume":"193","author":"Iliaki","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101645_bib52","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics","volume":"15","author":"Gutteridge","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2024.101645_bib53","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2024.101645_bib54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","article-title":"Metformin: An anti-diabetic drug to fight cancer","volume":"113","author":"Daugan","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib55","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1158\/1078-0432.CCR-09-2229","article-title":"Crosstalk between insulin\/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer","volume":"16","author":"Rozengurt","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib56","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin--mode of action and clinical implications for diabetes and cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2024.101645_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115873","article-title":"FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review","volume":"22","author":"Loschi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101645_bib58","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1261\/rna.2192803","article-title":"Lentivirus-delivered stable gene silencing by RNAi in primary cells","volume":"9","author":"Stewart","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.xcrm.2024.101645_bib59","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib60","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101645_bib61","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101645_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab108","article-title":"Venn diagrams in bioinformatics","volume":"22","author":"Jia","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xcrm.2024.101645_bib63","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2012-10-464677","article-title":"AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model","volume":"121","author":"Wunderlich","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101645_bib64","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/bloodadvances.2021005614","article-title":"Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia","volume":"5","author":"Zavorka Thomas","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101645_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Boussemart","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101645_bib66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2024.101645_bib67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124003598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124003598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T08:16:14Z","timestamp":1722154574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124003598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":67,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2666379124003598"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101645","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101645"}}